FDA to consider approval of new class of cholesterol drugs
PCSK9 inhibitors are self-injected every 2 weeks, and work by blocking substance that hinders liver's ability to remove cholesterol from blood
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Washington
A FEDERAL advisory committee this week will decide whether to recommend approval of the first in a new class of drugs that many experts believe could significantly cut the risk of strokes and heart attacks, a leading cause of death for Americans.
The highly anticipated new drugs have been shown in clinical trials to sharply reduce levels of bad, or LDL cholesterol, representing the first major advance in the area since widely used statin drugs hit the market in the late 1980s.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
